Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morella cerifera pollen, also known as Myrica cerifera pollen or southern bayberry, is an allergenic extract derived from the pollen of the Morella cerifera plant. [3, 4] It is a biologic product approved in the United States in 1965 and is used for diagnostic purposes in allergy testing. [3] Administered as an intradermal injection, it helps to establish the clinical relevance of specific allergens by inducing a localized allergic reaction (wheal and flare) in sensitized individuals. [1] This product is intended for diagnostic skin testing only and is not used for therapeutic treatment. [1, 2] It is distributed by companies such as ALK-Abello, Inc. as a non-standardized allergenic extract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Morella cerifera pollen.